Skip to content

Precigen PGEN Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
Gilead Sciences logo
Gilead SciencesGILD
+0.6×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
15.1×-4.3×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
14.2×-4.3×
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
32.6×+16.8×

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×

Where this comes from

Calculated from Precigen’s reported figures.

Based on the most recent quarter.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's current ratio?
Precigen (PGEN) reported current ratio of 4.8× in Q1 2026.
How has Precigen's current ratio changed year-over-year?
Precigen's current ratio increased by 36.6% year-over-year, from 3.5× to 4.8×.
What is the long-term trend for Precigen's current ratio?
Over 5 years (2020 to 2025), Precigen's current ratio has grown at a -2.7% compound annual growth rate (CAGR), from 3.5× to 3.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.